Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Huahai Pharmaceutical Co Ltd (600521) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥282.81 Million) by net assets (CN¥9.60 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zhejiang Huahai Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Zhejiang Huahai Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zhejiang Huahai Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Huahai Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Danieli & C RSP
LSE:0N4I
|
0.099x |
|
BILL Holdings, Inc.
SA:B2HI34
|
0.053x |
|
Guaranty Trust Holding Co. PLC GDR
LSE:GTCO
|
0.232x |
|
Zhende Medical Co Ltd
SHG:603301
|
0.017x |
|
China Everbright Environment Group Limited
F:CNE
|
-0.001x |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
0.031x |
|
Ninestar Corp
SHE:002180
|
0.016x |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
0.007x |
Annual Cash Flow Conversion Efficiency for Zhejiang Huahai Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Huahai Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.02 Billion | CN¥2.17 Billion | 0.241x | -10.35% |
| 2023-12-31 | CN¥8.25 Billion | CN¥2.22 Billion | 0.269x | +67.47% |
| 2022-12-31 | CN¥7.75 Billion | CN¥1.24 Billion | 0.160x | +15.85% |
| 2021-12-31 | CN¥6.78 Billion | CN¥938.43 Million | 0.138x | -40.13% |
| 2020-12-31 | CN¥6.72 Billion | CN¥1.56 Billion | 0.231x | -23.78% |
| 2019-12-31 | CN¥5.78 Billion | CN¥1.75 Billion | 0.304x | +1780.57% |
| 2018-12-31 | CN¥4.21 Billion | CN¥67.90 Million | 0.016x | -85.06% |
| 2017-12-31 | CN¥5.05 Billion | CN¥546.24 Million | 0.108x | +14.22% |
| 2016-12-31 | CN¥4.58 Billion | CN¥433.10 Million | 0.095x | +80.21% |
| 2015-12-31 | CN¥3.72 Billion | CN¥195.31 Million | 0.052x | -47.82% |
| 2014-12-31 | CN¥3.27 Billion | CN¥328.61 Million | 0.101x | -38.04% |
| 2013-12-31 | CN¥3.02 Billion | CN¥490.29 Million | 0.162x | +29.80% |
| 2012-12-31 | CN¥1.95 Billion | CN¥243.83 Million | 0.125x | -3.12% |
| 2011-12-31 | CN¥1.53 Billion | CN¥197.51 Million | 0.129x | -43.15% |
| 2010-12-31 | CN¥1.32 Billion | CN¥299.47 Million | 0.227x | -13.25% |
| 2009-12-31 | CN¥1.21 Billion | CN¥317.44 Million | 0.262x | +243.02% |
| 2008-12-31 | CN¥1.10 Billion | CN¥84.20 Million | 0.076x | -45.45% |
| 2007-12-31 | CN¥975.52 Million | CN¥136.52 Million | 0.140x | +57.99% |
| 2006-12-31 | CN¥875.40 Million | CN¥77.54 Million | 0.089x | +33.34% |
| 2005-12-31 | CN¥802.34 Million | CN¥53.30 Million | 0.066x | -68.13% |
| 2004-12-31 | CN¥785.53 Million | CN¥163.73 Million | 0.208x | +201.31% |
| 2003-12-31 | CN¥685.42 Million | CN¥47.41 Million | 0.069x | -92.60% |
| 2002-12-31 | CN¥80.56 Million | CN¥75.34 Million | 0.935x | +79.90% |
| 2001-12-31 | CN¥72.15 Million | CN¥37.51 Million | 0.520x | -- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and pol… Read more